Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) earns a spot in our list of the top 10 stocks under $5 that could triple.

Growing Optimism About ProQR Therapeutics N.V. (PRQR)’s RNA Editing Platform and Future Clinical Catalysts

As of March 19, 2026, analysts remain confident in ProQR Therapeutics N.V. (NASDAQ:PRQR), with 100% maintaining “Buy” ratings. The consensus price target of $9.44 implies a 448.56% upside, reflecting growing optimism about the company’s RNA editing platform and future clinical catalysts.

ProQR Therapeutics N.V. (NASDAQ:PRQR) reported full-year 2025 results on March 12, 2026. The company noted the ongoing development of AX-0810 in a Phase 1 trial, with target engagement data anticipated in 1H 2026.

CEO Daniel de Boer described this as a key milestone for ProQR Therapeutics N.V. (NASDAQ:PRQR), which follows pipeline expansion with AX-2402 in Rett syndrome and AX-2911 in MASH. Furthermore, the business received $4.50 million in milestone payments under its agreement with Eli Lilly, providing runway into mid-2027. Early AX-0810 studies showed encouraging pharmacokinetics and safety, with plans to include patients with PSC.

During the quarter, cash decreased to $105.96 million, R&D increased to $51.26 million, and net loss widened to $48.62 million, or $0.46 per share, while ProQR Therapeutics N.V. (NASDAQ:PRQR)’s continued pipeline development remains a central focus for investors.

ProQR Therapeutics N.V. (NASDAQ:PRQR) is a clinical-stage biotechnology company focused on developing RNA therapeutics for severe rare genetic diseases, including inherited retinal impairments, using its patented platform to address unmet medical needs.

While we acknowledge the risk and potential of PRQR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRQR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.